Discovery MR750, MRI recall, GE, FDA recall
Feature | Dave Fornell

GE Healthcare initiated a voluntary field corrective action for all of its magnetic resonance imaging (MRI) systems with superconducting magnets that were manufactured from 1985 through today. The U.S. Food and Drug Administration (FDA) classified it as a Class 1 product recall Feb. 18.

Home February 20, 2015
Home
News

Biotronik announced the completion of enrollment in the BIOSOLVE-II trial ā€” a clinical study investigating the safety and performance of DREAMS (DRug Eluting Absorbable Metal Scaffold).

Home February 19, 2015
Home
News

Three out of five healthcare IT professionals believe that government mandates are having a negative effect on their industry, according to a study conducted by Peak 10, a national information technology (IT) infrastructure and cloud services provider. The majority (94 percent) also noted that complying with regulations influences IT strategy and decision-making. With rare exception, respondents claimed they lack the expertise necessary to navigate the maze of government regulations.

Home February 19, 2015
Home
Lutonix, drug eluting balloon, drug coated balloon
Feature | Drug-Eluting Balloons | Dave Fornell

Drug-eluting balloons (DEBs) have been one of the long-awaited new transcatheter technologies to help reduce high restenosis rates in peripheral artery disease (PAD). The U.S. Food and Drug Administration (FDA) cleared C. R. Bardā€™s Lutonix 035 DEB in November 2014 and Medtronicā€™s In.Pact Admiral DEB in January 2015. Both are indicated for use in the superficial femoral and popliteal arteries in the upper leg.

Home February 19, 2015
Home
News

At the SPIE Medical Imaging Conference, ContextVision exhibited results from research conducted in collaboration with Texas Instruments and High Performance Consulting on 3-D adaptive filtering for improved image quality on portable medical devices. Bjƶrn Norell, research scientist at ContextVision, presented the findings.

Home February 19, 2015
Home
Technology

Calgary Scientific Inc. announced the release of ResolutionMD 5.0, which offers better access to health information, supports increased teamwork and enhances communication among practitioners and patients.

Home February 19, 2015
Home
News

Looking to ā€œbypass the ordinary,ā€ during last weekā€™s episode titled: ā€œThe Bed's Too Big Without You,ā€ the Greyā€™s Anatomy team at Seattle Grace Hospital was challenged with treating a radical tumor in the chest. After printing a 3-D model of the surgical area, Dr. Alex Karev commented that the best course of action to access the chest and successfully remove the mass would involve ā€œthe McGinn technique.ā€

Home February 18, 2015
Home
iRhythm, ZIO Service, arrhythmia detection, wearable, Holter monitors
Feature

iRhythm Technologies Inc. announced the study, ā€œCost Analysis and Clinical Outcomes of Ambulatory Care Monitoring in Medicare Patients,ā€ was published in the Journal of Health Economics and Outcomes Research. The study assessed the costs incurred in the diagnosis, additional monitoring and following clinical events after the initial use of the Holter monitor among Medicare patients with arrhythmia.

Home February 18, 2015
Home
Technology

Cerner Corp. and development partner Mortara Instrument have joined together to introduce CareAware Waveform Management. The system displays waveforms and other physiological data from patient monitoring systems and integrates them into the electronic health record (EHR).

Home February 18, 2015
Home
Radiation dose monitoring software analytics offered by Sectra.
Feature | Radiation Dose Management | Dave Fornell

Cardiac imaging accounts for about one-third of the source of X-ray radiation dose for all medical imaging. Expanding use of computed tomography (CT) for cardiac evaluations, use of nuclear imaging for myocardial perfusion exams and more complex transcatheter procedures in the cath lab have all increased patient exposure in recent years.

Home February 18, 2015
Home
News

The spirit of collaboration to improve health with information technology came to Cleveland, Ohio, when the Integrating the Healthcare Enterprise (IHE) North American Connectathon 2015 opened in January 2015. Almost 100 organizations and 555 engineers attended this annual testing event.

Home February 18, 2015
Home
Technology

Physicians who use the clinical reference tool, DynaMed from EBSCO Health, can now access the valuable, evidence-based content anywhere with the new DynaMedmobile app. The new app has been redesigned to make it easier and faster for physicians to find answers to clinical questions.

Home February 18, 2015
Home
Adam Greenbaum, M.D., and William O'Neill, M.D., perform a TAVR procedure in a hybrid cath lab at Henry Ford Hospital in Detroit. Structural heart
Feature | Lynn Tangorra

Transcatheter aortic valve replacement (TAVR) is not only a breakthough minimally invasive medical therapy, but offers a new business opportunity for hospitals that begin a program. The technology is viewed as cutting edge not only with clinicians, but also among the general public. This can be leveraged to promote the hospital as a cutting-edge facility and help attract new patients. However, creating these programs requires long-term financial, professional and equipment commitments, which may not be right for all hospitals. There are also concerns that a proliferation of TAVR centers may make programs less profitable and reduce the proficiency of any one center as patient volumes decrease if patients are spread between many competing hospitals.

Home February 17, 2015
Home
News

Most ā€œrisk calculatorsā€ used by clinicians to gauge a patientā€™s chances of suffering a heart attack and guide treatment decisions appear to significantly overestimate the likelihood of a heart attack, according to results of a study by investigators at Johns Hopkins and other institutions.

Home February 17, 2015
Home
News

Micell Technologies, Inc. announced the commercial availability of the MiStent Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES) in Europe. Stentys, Micellā€™s distribution partner in Paris, plans a controlled launch in Western Europe followed by a full commercial launch for the second half of 2015 in selected countries within Europe, Middle East, Southeast Asia and Latin America.

Home February 17, 2015
Home
Subscribe Now